Video

D.Juric scans the horizon of PI3K and other inhibitors that are present in a whole range of common and rare cancers and that have already found single-agent therapies offering benefit to patients. The next step will be to explore combination therapies to expand the potential of these inhibitors.http://www.impakt.org

Latest News